Variantyx is a leading genomics company specializing in advanced diagnostic testing and genomic analysis to produce personalized medicines. Utilizing state-of-the-art sequencing technologies and bioinformatics tools, Variantyx offers comprehensive genetic testing services aimed at identifying and characterizing complex genetic variations. Their scientific approach enables precise diagnosis of rare and inherited disorders, providing clinicians and patients with valuable insights into genetic disease mechanisms. Variantyx leverages the power of whole genome and other new sequencing technologies, along with intelligent analysis technology for prenatal testing, rare genetic disorder diagnosis, precision oncology treatment, and even wellness testing for healthy adults.

Variantyx

IT Service Desk Intern

Senior Accountant

IT Service Desk Technician

Variantyx and FDNA Announce Integration of their Applications to Facilitate Rare Disease Diagnosis - Business Wire

 Variantyx Secures $20M in Series C 

Explore rapid testing with Variantyx

Variantyx Launches Its RareDx Program, Providing Clinical Whole Genome Testing to Enrolled Patients - Business Wire

 Variantyx scoops up $20M for whole genome sequencing-based testing methodology 

Exciting news! Our Lightning rapid genome test is now available for patients of all ages. Choose from neonatal, pediatric and standard analysis offerings. All three are lightning fast, ensuring timely answers to guide medical management. Learn more here -> https://lnkd.in/eXyxG-UH


					


	
	
	
	
	
	
	
	
	
	

					Variantyx
					
				

It's been one month since we launched Genomic Unity® 2.0 and the response has been amazing. See why everyone is talking about our new combined short and long-read genome sequencing test  ➡️  https://lnkd.in/eGsD7E4i

 Variantyx raises $36m to commercialise genomic diagnostics 

Daryl Spinner, Variantyx


								Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase									

The next evolution of genomic testing is here. Today! Read the press release 🧬 Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0 👉 https://lnkd.in/es73ib_W

If you're at #NSGC24, stop by Variantyx booth 426 to find out more about Genomic Unity 2.0 - the ultimate diagnostic test.

 Variantyx Raises $41.5M in Second Series C Funding Round 

Today we celebrate genetic counselors everywhere! Thank you for the support you provide to patients and their families. #GCawareness #GeneticCounselorAwarenessDay

 Variantyx Raises $36M in Private Financing 

Understanding Variantyx Reports

With treatment options available for #RettSyndrome, comprehensive identification of MECP2 variants through #wholegenome testing has become even more important. Download our case study describing a partial exon MECP2 deletion to see why Seeing More with Variantyx testing makes a difference 🔎 https://ow.ly/um6750TMKW9

Learn More About Ataxia Testing With Variantyx

The Variantyx Difference

Thanks to the comprehensive analysis power of IriSight™ #wholegenome testing, we find that ~6% of prenatal cases result in a dual diagnosis. Download our latest prenatal case study to see how a mix of small sequence changes and single exon deletions was uniquely detected in a single test 👉 https://ow.ly/hLL450T8ZkR

 Expanded STR Detection Capability Enables Variantyx to Diagnose Additional Genetic Disorders 

Learn More About Mitochondrial Disorder Testing With Variantyx

 Variantyx: Molecular Diagnostics Company Closes $36 Million In Funding 

Watch to see how Genomic Unity® whole genome testing made a Segawa syndrome diagnosis following multiple negative tests using other technologies  ▶️  https://ow.ly/WGXH50TIUNY

Variantyx Launches Genomic Intelligence® Clinical Diagnostic Platform - Business Wire

 Framingham firm debuts genome test to check for genetic ... 

Whole-genome analysis company Variantyx gets $41.5M for precision oncology solutions - Fierce healthcare


								Expanded STR Detection Capability Enables Variantyx to Diagnose Additional Genetic Disorders									


								Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis									

Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase - Business Wire

 Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase 

Learn More About Epilepsy Testing With Variantyx

 Outsized Closes Series A Funding 

Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders - Business Wire

 Robert Bosch Venture Capital joins Variantyx's US $26 million Series C funding round 


								Variantyx updates secondary findings reporting policy to ACMG v3.2									

Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint - Business Wire

Variantyx raises $36m to commercialise genomic diagnostics - Yahoo Finance

Robert Bosch Venture Capital joins Variantyx’s US $26 million Series C funding round - bosch-presse.de

 Variantyx Raises $36M in Funding 

Check out this week's GenomeWeb article featuring Genomic Unity® 2.0 combined short and long-read genome sequencing 🧬 https://lnkd.in/ew4NrCzy

 Robert Bosch Venture Capital Invests Approx. $26M in Variantyx 


								Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0									

 Variantyx–SEVERAL: investment, 202404 financing round $36m from existing investors 

ONT long-read WGS for variant discovery and orthogonal confirmation of short read WGS derived genetic variants in clinical genetic testing - Frontiers

We're looking forward Christine Stanley's #NSGC24 lunch symposia tomorrow on the next evolution in genomic testing. Can't make it? Come see us at booth 426.

 Technology-Driven Precision Medicine Company Variantyx Secures $41.5M in Funding 

Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0 - Business Wire

 Variantyx Launches Its Whole Genome Sequencing (WGS)-Based In-Silico Panel Program at National Society of Genetic Counselors Annual Conference 

#NiemannPick awareness month is off to a positive start with the FDA’s recent approval of two Type C treatments: Aqneursa and Miplyffa. For the most comprehensive analysis of NPC1 and NPC2 genes available, choose Genomic Unity #wholegenome testing. Learn more about the Variantyx difference ➡️ https://lnkd.in/eETwQujq

#WeSeeMore

 Variantyx Raises Additional Funding 

 8 Whole Genome Sequencing Companies for Precision Health 


								Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint									

 Variantyx: Genomic Precision Medicine Company To Expand With New Funding Round 

 Variantyx Announces Additional Investment Enabling Rapid Expansion of Its Commercial Footprint 

Israel's all-in-one test for diagnosis of rare inherited disorders - The Jerusalem Post


								Variantyx Combines Long and Short Reads for Rare Disease Whole-Genome Diagnostic Test									

Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round - Business Wire

Variantyx

Business:

About: